The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review

Table 1

Main ongoing clinical trials with benralizumab.

Trial	Phase	Conditions	Treatments	Status
NCT03563066	II	Atopic dermatitis	Benralizumab placebo	Completed
NCT04605094	II	Atopic dermatitis	Benralizumab placebo	Active
NCT04612725	IIb	Chronic spontaneous urticaria	Benralizumab placebo	Active
NCT03183024	IV	Chronic idiopathic urticaria	Benralizumab placebo	Completed
NCT01227278	II	Chronic obstructive pulmonary disease	Benralizumab placebo	Completed
NCT02138916	III	Chronic obstructive pulmonary disease	Benralizumab placebo	Completed
NCT02155660	III	Chronic obstructive pulmonary disease	Benralizumab placebo	Completed
NCT04098718	II	Chronic obstructive pulmonary disease	Benralizumab placebo	Recruiting
NCT04053634	III	Chronic obstructive pulmonary disease	Benralizumab placebo	Recruiting
NCT05273359	II	Chronic obstructive pulmonary disease	Benralizumab placebo	Not yet recruiting
NCT03401229	III	Nasal polyps	Benralizumab placebo	Completed
NCT04185012	III	Nasal polyps	Benralizumab placebo	Recruiting
NCT03450083	II	Chronic rhinosinusitis with nasal polyps	Benralizumab placebo	Completed
NCT04157335	III	Chronic rhinosinusitis with nasal polyps	Benralizumab placebo	Recruiting
NCT02772419	II	Eosinophilic chronic rhinosinusitis	Benralizumab placebo	Completed
NCT03473977	II/III	EGID	Benralizumab placebo	Completed
NCT04543409	III	EGID	Benralizumab placebo	Active
NCT05251909	III	EGID∗	Benralizumab placebo	Recruiting
NCT04191304	III	Hypereosinophilic syndrome	Benralizumab placebo	Recruiting
NCT02130882	II/III	Hypereosinophilic syndrome	Benralizumab placebo	Not yet recruiting
NCT04157348	III	Eosinophilic granulomatous vasculitis	Benralizumab mepolizumab	Recruiting
NCT04612790	III	Bullous pemphigoid	Benralizumab placebo	Recruiting
NCT04108962	IV	Allergic bronchopulmonary aspergillosis	Benralizumab placebo	Withdrawn

Eosinophilic gastroenteritis or eosinophilic gastritis. Difficult to find eligible patients.